Success Metrics

Active Trials
4(44%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
5
56%
Ph phase_3
3
33%

Phase Distribution

1

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(8)
Other(1)

Detailed Status

Recruiting4
Not yet recruiting4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 25 (55.6%)
Phase 33 (33.3%)

Trials by Status

recruiting444%
not_yet_recruiting444%
unknown111%

Recent Activity

4 active trials
Showing 5 of 9
recruitingphase_3

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

NCT07441460
recruitingphase_2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

NCT05582499
not_yet_recruitingphase_2

HB1801 Combined Treatment of HER2-positive Breast Cancer

NCT07116824
not_yet_recruitingphase_2

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

NCT07083505
recruitingphase_3

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

NCT05838066
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07441460Phase 3

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Recruiting
NCT05582499Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
NCT07116824Phase 2

HB1801 Combined Treatment of HER2-positive Breast Cancer

Not Yet Recruiting
NCT07083505Phase 2

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Not Yet Recruiting
NCT05838066Phase 3

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Recruiting
NCT06747338Phase 3

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Recruiting
NCT06682611Phase 1

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Not Yet Recruiting
NCT06319313Phase 2

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT05863325Phase 2

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9